 WILMINGTON, Del., Jan. 04, 2021 GLOBE NEWSWIRE -- Prelude Therapeutics Incorporated Prelude or the Company Nasdaq: PRLD, a clinical-stage precision oncology company, today announced that it has commenced a public offering of 1,750,000 shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission SEC. All shares of common stock to be sold in the offering will be sold by Prelude. In addition, Prelude expects to grant the underwriters a 30-day option to purchase up to an additional 262,500 shares of common stock at the public offering price, less underwriting discounts and commissions. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 